Wanbury Share Price

  • 265.81-4.63 (-1.72%)
  • Volume: 91,589
  • Closed
  • Last Updated On: 22 Apr, 2025, 03:33 PM IST
Loading...

Wanbury Share Price

  • 265.81-4.63 (-1.72%)
  • Volume: 91,589
Advertisment

Wanbury share price insights

View All
  • Company witnessed QoQ revenue decline of 17.52%, which is lowest in the last 3 years. (Source: Consolidated Financials)

  • Stock gave a 3 year return of 226.82% as compared to Nifty Smallcap 100 which gave a return of 55.24%. (as of last trading session)

  • Company has spent 5.07% of its operating revenues towards interest expenses and 15.1% towards employee cost in the year ending Mar 31, 2024. (Source: Consolidated Financials)

  • Stock generated 226.82% return as compared to Nifty Pharma which gave investors 52.86% return over 3 year time period. (as of last trading session)

  • Wanbury Ltd. share price moved down by -1.72% from its previous close of Rs 270.44. Wanbury Ltd. stock last traded price is 265.81

    Share PriceValue
    Today/Current/Last265.81
    Previous Day270.44271.15

InsightsWanbury

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    Key Metrics

    PE Ratio
    (x)
    19.84
    EPS - TTM
    (₹)
    13.40
    MCap
    (₹ Cr.)
    871.07
    Sectoral MCap Rank
    79
    PB Ratio
    (x)
    31.70
    Div Yield
    (%)
    0.00
    Face Value
    (₹)
    10.00
    Beta

    Beta

    1 Month0.60
    3 Months0.43
    6 Months0.71
    1 Year1.08
    3 Years1.02
    0.60
    VWAP
    (₹)
    268.78
    52W H/L
    (₹)
    323.53 / 131.20

    Wanbury Ltd Share Price Returns

    1 Day-1.72%
    1 Week4.62%
    1 Month10.33%
    3 Months9.27%
    1 Year66.55%
    3 Years221.22%
    5 Years1019.2%

    ET Stock ScreenersTop Score Companies

    Check whether Wanbury Ltd belongs to analysts' top-rated companies list?

    View Stock Screeners

    Wanbury Share Analysis

    Unlock Stock Score, Analyst' Ratings & Recommendations

    Share Analysis Non Prime User
    • View Stock Score on a 10-point scale
    • See ratings on Earning, Fundamentals, Valuation, Risk & Price
    • Check stock performance
    JOIN ET PRIME

    Wanbury Share Recommendations

    No Recommendations details available for this stock.
    Check out other stock recos.

    Wanbury Financials

    • Insights

      • Quarterly Topline Performance

        Company witnessed QoQ revenue decline of 17.52%, which is lowest in the last 3 years. (Source: Consolidated Financials)
      • Employee & Interest Expense

        Company has spent 5.07% of its operating revenues towards interest expenses and 15.1% towards employee cost in the year ending Mar 31, 2024. (Source: Consolidated Financials)
      Quarterly | AnnualDec 2024Sep 2024Jun 2024Mar 2024Dec 2023
      Total Income134.29162.82132.05140.33146.19
      Total Income Growth (%)-17.5223.30-5.90-4.010.67
      Total Expenses122.83144.51123.4298.97127.67
      Total Expenses Growth (%)-15.0017.0824.71-22.49-2.06
      EBIT11.4618.328.6341.3718.52
      EBIT Growth (%)-37.44112.24-79.14123.4124.63
      Profit after Tax (PAT)1.228.021.0433.6310.27
      PAT Growth (%)-84.81672.95-96.92227.4039.54
      EBIT Margin (%)8.5311.256.5429.4812.67
      Net Profit Margin (%)0.914.920.7923.977.03
      Basic EPS (₹)0.382.440.3210.283.13
      Quarterly | AnnualDec 2024Sep 2024Jun 2024Mar 2024Dec 2023
      Total Income134.29162.82132.05140.33146.19
      Total Income Growth (%)-17.5223.30-5.90-4.010.67
      Total Expenses122.83144.51123.42124.52127.67
      Total Expenses Growth (%)-15.0017.08-0.88-2.47-2.06
      EBIT11.4618.328.6315.8118.52
      EBIT Growth (%)-37.44112.24-45.41-14.6224.63
      Profit after Tax (PAT)1.228.021.048.0810.27
      PAT Growth (%)-84.81672.94-87.16-21.3839.54
      EBIT Margin (%)8.5311.256.5411.2712.67
      Net Profit Margin (%)0.914.920.795.767.03
      Basic EPS (₹)0.382.440.322.473.14
      Quarterly | Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Total Revenue578.64500.56512.69394.92368.59
      Total Revenue Growth (%)15.60-2.3729.827.14-8.01
      Total Expenses547.86510.25507.93407.33386.56
      Total Expenses Growth (%)7.370.4624.705.37-9.19
      Profit after Tax (PAT)55.96-10.4081.47-12.6164.46
      PAT Growth (%)--112.76--119.56-
      Operating Profit Margin (%)10.412.344.962.714.05
      Net Profit Margin (%)9.72-2.0815.93-3.2117.54
      Basic EPS (₹)17.10-3.1825.29-5.0426.90
      Quarterly | Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Total Revenue578.64500.56512.69394.92368.59
      Total Revenue Growth (%)15.60-2.3729.827.14-8.01
      Total Expenses547.86510.25507.93407.33386.56
      Total Expenses Growth (%)7.370.4624.705.37-9.19
      Profit after Tax (PAT)30.40-10.4081.47-12.6164.46
      PAT Growth (%)--112.76--119.56-
      Operating Profit Margin (%)10.412.344.962.714.05
      Net Profit Margin (%)5.28-2.0815.93-3.2117.54
      Basic EPS (₹)9.29-3.1825.29-5.0426.90

      All figures in Rs Cr, unless mentioned otherwise

    • Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Total Assets343.49303.87352.55289.18278.69
      Total Assets Growth (%)13.04-13.8121.913.76-2.57
      Total Liabilities315.55336.69375.97445.42422.15
      Total Liabilities Growth (%)-6.28-10.45-15.595.51-14.77
      Total Equity27.94-32.82-23.42-156.24-143.45
      Total Equity Growth (%)-----
      Current Ratio (x)0.740.390.480.280.30
      Total Debt to Equity (x)3.94-1.95-2.86-0.57-0.87
      Contingent Liabilities70.291,033.26908.54889.881,012.55
      Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Total Assets343.49302.25351.00287.60277.16
      Total Assets Growth (%)13.64-13.8922.043.77-2.62
      Total Liabilities315.55309.50348.81418.26395.00
      Total Liabilities Growth (%)1.95-11.27-16.605.89-15.63
      Total Equity27.94-7.262.19-130.66-117.83
      Total Equity Growth (%)--431.51---
      Current Ratio (x)0.740.420.520.300.32
      Total Debt to Equity (x)3.94-8.8430.64-0.68-1.06
      Contingent Liabilities70.29945.26908.54862.781,009.04

      All figures in Rs Cr, unless mentioned otherwise

    • Insights

      • Increase in Cash from Investing

        Company has used Rs 16.63 cr for investing activities which is an YoY increase of 88.12%. (Source: Consolidated Financials)
      Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Net Cash flow from Operating Activities3.9819.8040.5216.6844.13
      Net Cash used in Investing Activities-16.63-8.840.598.0463.66
      Net Cash flow from Financing Activities14.55-31.99-28.58-17.39-107.87
      Net Cash Flow1.91-21.0312.537.34-0.08
      Closing Cash & Cash Equivalent3.401.4922.5310.002.66
      Closing Cash & Cash Equivalent Growth (%)127.54-93.37125.23275.84-2.88
      Total Debt/ CFO (x)27.643.241.655.302.82
      Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Net Cash flow from Operating Activities4.0219.8040.5216.6844.13
      Net Cash used in Investing Activities-16.63-8.840.598.0463.66
      Net Cash flow from Financing Activities14.55-31.99-28.58-17.39-107.87
      Net Cash Flow1.94-21.0312.537.34-0.09
      Closing Cash & Cash Equivalent3.401.4622.499.962.62
      Closing Cash & Cash Equivalent Growth (%)133.59-93.53125.72279.91-3.16
      Total Debt/ CFO (x)27.373.241.655.302.82

      All figures in Rs Cr, unless mentioned otherwise

    • Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Return on Equity (%)200.260.00-347.880.00-44.93
      Return on Capital Employed (%)46.34-70.89-351.22-16.12-46.06
      Return on Assets (%)16.29-3.4223.10-4.3523.13
      Interest Coverage Ratio (x)2.501.131.790.890.75
      Asset Turnover Ratio (x)1.781.521.601.391.30
      Price to Earnings (x)8.54-11.753.41-16.470.71
      Price to Book (x)17.09-3.72-11.86-1.33-0.32
      EV/EBITDA (x)7.977.578.6713.926.23
      EBITDA Margin (%)12.674.827.205.206.69
      Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Return on Equity (%)108.790.003,724.180.00-54.70
      Return on Capital Employed (%)46.34129.25138.00-26.28-221.47
      Return on Assets (%)8.85-3.4323.21-4.3823.25
      Interest Coverage Ratio (x)2.501.131.790.890.75
      Asset Turnover Ratio (x)1.781.531.601.391.31
      Price to Earnings (x)15.72-11.753.41-16.470.71
      Price to Book (x)17.09-16.82127.06-1.59-0.39
      EV/EBITDA (x)7.977.578.6713.926.24
      EBITDA Margin (%)12.674.827.205.206.69

    Financial InsightsWanbury

    • Income (P&L)
    • Cash Flow
      • Quarterly Topline Performance

        Company witnessed QoQ revenue decline of 17.52%, which is lowest in the last 3 years. (Source: Consolidated Financials)

      • Employee & Interest Expense

        Company has spent 5.07% of its operating revenues towards interest expenses and 15.1% towards employee cost in the year ending Mar 31, 2024. (Source: Consolidated Financials)

      • Increase in Cash from Investing

        Company has used Rs 16.63 cr for investing activities which is an YoY increase of 88.12%. (Source: Consolidated Financials)

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    Wanbury Technicals

    • Stock doesn't have any Buy/Sell Signals.

    • Price Analysis Data details are not available.

    • Pivot Levels

      R1R2R3PIVOTS1S2S3
      Classic-------

      Average True Range

      5 DAYS14 DAYS28 DAYS
      ATR---

    Wanbury Ltd Peer Comparison

    • Insights

      • Stock Returns vs Nifty Smallcap 100

        Stock gave a 3 year return of 226.82% as compared to Nifty Smallcap 100 which gave a return of 55.24%. (as of last trading session)
      • Stock Returns vs Nifty Pharma

        Stock generated 226.82% return as compared to Nifty Pharma which gave investors 52.86% return over 3 year time period. (as of last trading session)
      • 1D
      • 1W
      • 1M
      • 3M
      • 6M
      • 1Y
      • 5Y
      Loading...
    • Insights

      • Stock Returns vs Nifty Smallcap 100

        Stock gave a 3 year return of 226.82% as compared to Nifty Smallcap 100 which gave a return of 55.24%. (as of last trading session)
      • Stock Returns vs Nifty Pharma

        Stock generated 226.82% return as compared to Nifty Pharma which gave investors 52.86% return over 3 year time period. (as of last trading session)

      Ratio Performance

      NAMEP/E (x)P/B (x)ROE %ROCE %ROA %Rev CAGR [3Yr]OPMNPMBasic EPSCurrent RatioTotal Debt/ Equity (x)Total Debt/ CFO (x)
      Wanbury Ltd19.8431.16200.2646.3416.2913.4310.419.7217.100.743.9427.64
      Kopran Ltd20.311.9610.3714.516.857.1912.388.2910.572.080.202.29
      Anuh Pharma17.352.9920.6226.8413.4714.0512.159.2811.982.200.010.16
      Medicamen Bio75.962.885.288.323.7116.799.745.297.501.890.15-4.57
      Kilitch Drug29.003.228.2814.376.0830.3316.378.799.172.270.18-216.31
      Add More
      Annual Ratios (%)

      Choose from Peers

      • Nectar Lifesc
      • Ind-Swift Labs
      • Albert David
      • Medico Remedies
      • Zim Laboratories

      Choose from Stocks

      Peers InsightsWanbury

      • Stock Returns vs Nifty Smallcap 100

        Stock gave a 3 year return of 226.82% as compared to Nifty Smallcap 100 which gave a return of 55.24%. (as of last trading session)

      • Stock Returns vs Nifty Pharma

        Stock generated 226.82% return as compared to Nifty Pharma which gave investors 52.86% return over 3 year time period. (as of last trading session)

      Do you find these insights useful?

      • hate it

      • meh

      • love it

      Wanbury Shareholding Pattern

      • Loading...
        Showing Wanbury Shareholding as on Mar 2025
        CategoryMar 2025Dec 2024Sep 2024Jun 2024
        Promoters39.7639.7639.7739.79
        Pledge76.7476.7476.7476.74
        FII1.550.841.020.22
        DII0.000.000.000.00
        Mutual Funds0.000.000.000.00
        Others58.6959.4059.2059.99
      • Showing Shareholding as on Mar 2025
        CategoryNo. of SharesPercentage% Change QoQ
        Promoters1,30,29,56139.76 %0.00
        Pledge99,98,30476.74 %0.00
        FII5,09,0761.55 %0.71
        DII660.00 %0.00
        MF660.00 %0.00
        Others1,92,31,79558.69 %-0.70

      Wanbury MF Ownership

      MF Ownership details are not available.

      Wanbury Corporate Actions

      • Meeting DateAnnounced onPurposeDetails
        Feb 20, 2025Jan 24, 2025EGMBook closure from Feb 14, 2025 to Feb 20, 2025
        Feb 12, 2025Feb 10, 2025Board MeetingQuarterly Results & Others
        Nov 13, 2024Nov 05, 2024Board MeetingQuarterly Results
        Sep 27, 2024Sep 17, 2024AGMA.G.M.
        Aug 12, 2024Aug 06, 2024Board MeetingQuarterly Results
      • TypeDividendDividend per ShareEx-Dividend DateAnnounced on
        Final 10%1.0Jul 29, 2010May 31, 2010
        Final 5%0.5Mar 12, 2009Dec 31, 2008
        Final 20%2.0Sep 13, 2007Jun 29, 2007
        Final 15%1.5Sep 07, 2006Jun 28, 2006
        Interim 5%0.5Feb 20, 2006Jan 31, 2006
      • All TypesEx-DateRecord DateAnnounced onDetails
        Rights--Sep 02, 1994Rights ratio: 1 share for every 1 held at a price of Rs 10.0

      About Wanbury

      Wanbury Ltd., incorporated in the year 1988, is a Small Cap company (having a market cap of Rs 871.07 Crore) operating in Pharmaceuticals sector. Wanbury Ltd. key Products/Revenue Segments include Pharmaceuticals, Export Incentives and Scrap for the year ending 31-Mar-2023. Show More

      • Executives

      • Auditors

      • KC

        K Chandran

        Vice Chairman & Whole Time Dir
        MK

        Mohan Kumar Rayana

        Whole Time Director
        AV

        Anupama Vaidya

        Ind. Non-Executive Woman Director
        PD

        Pravin Dilip Pawar

        Ind. Non-Executive Director
        Show More
      • Kapoor & Parekh Associates
        V Parekh & Associates

      Key Indices Listed on

      -

      Address

      BSEL Tech Park, B-Wing,10th Floor, Sector 30-A,Opp. Vashi Railway Station,New Mumbai, Maharashtra - 400703

      FAQs about Wanbury share

      • 1. What's the Wanbury Ltd share price today?
        Wanbury Ltd share price is Rs 265.81 as on 22 Apr, 2025, 03:56 PM IST. Wanbury Ltd share price is down by 1.72% based on previous share price of Rs. 240.65. In last 1 Month, Wanbury Ltd share price moved up by 10.33%.
      • 2. What are the Wanbury Ltd quarterly results?
        Total Revenue and Earning for Wanbury Ltd for the year ending 2024-03-31 was Rs 578.64 Cr and Rs 55.96 Cr on Consolidated basis. Last Quarter 2024-12-31, Wanbury Ltd reported an income of Rs 134.29 Cr and profit of Rs 1.22 Cr.
      • 3. How can I quickly analyze Wanbury Ltd stock?
        Key Metrics for Wanbury Ltd are:
        • Price to Book ratio of Wanbury Ltd is 31.70
      • 4. What dividend is Wanbury Ltd giving?
        An equity Final dividend of Rs 1 per share was declared by Wanbury Ltd. on 31 May 2010. So, company has declared a dividend of 10% on face value of Rs 10 per share. The ex dividend date was 29 Jul 2010.
      • 5. Who's the owner of Wanbury Ltd?
          • Promoter holding have gone down from 39.79 (30 Jun 2024) to 39.76 (31 Mar 2025)
          • Domestic Institutional Investors holding has not changed in last 9 months and holds 0.0 stake as on 31 Mar 2025
          • Foreign Institutional Investors holding has gone up from 0.22 (30 Jun 2024) to 1.55 (31 Mar 2025)
          • Other investor holding have gone down from 59.99 (30 Jun 2024) to 58.69 (31 Mar 2025)
      • 6. What are the returns for Wanbury Ltd share?
        Return Performance of Wanbury Ltd Shares:
        • 1 Week: Wanbury Ltd share price moved up by 4.62%
        • 1 Month: Wanbury Ltd share price moved up by 10.33%
        • 3 Month: Wanbury Ltd share price moved up by 9.27%
        • 6 Month: Wanbury Ltd share price moved up by 14.77%
      • 7. What is 52 week high/low of Wanbury Ltd share price?
        In last 52 weeks Wanbury Ltd share had a high price of Rs 323.53 and low price of Rs 131.20
      • 8. Who's the chairman of Wanbury Ltd?
        K Chandran is the Vice Chairman & Whole Time Dir of Wanbury Ltd
      • 9. What is the market cap of Wanbury Ltd?
        Within the Pharmaceuticals sector, Wanbury Ltd stock has a market cap rank of 79. Wanbury Ltd has a market cap of Rs 871.07 Cr.
      • 10. Who are the peers for Wanbury Ltd in Pharmaceuticals sector?
        Within Pharmaceuticals sector Wanbury Ltd, Nectar Lifesciences Ltd., Kopran Ltd., Albert David Ltd., Medicamen Biotech Ltd., Medico Remedies Ltd., Ind-Swift Laboratories Ltd., Anuh Pharma Ltd., Zim Laboratories Ltd., Kilitch Drugs(I) Ltd. and Lyka Labs Ltd. are usually compared together by investors for analysis.

      Trending in Markets

      Top Gainers As on 03:59 PM | 22 Apr 2025

      Alok Industries19.49
      3.02 (18.34%)
      Data Patterns (India)2,130.10
      171.10 (8.74%)
      Waaree Energies2,615.90
      171.71 (7.03%)
      KFIN Technologies1,284.40
      83.61 (6.97%)
      Trident Ltd29.28
      1.88 (6.83%)

      Top Losers As on 03:31 PM | 22 Apr 2025

      Chola Inv Finance1,566.40
      -93.40 (-5.63%)
      IndusInd Bank787.50
      -40.71 (-4.92%)
      Just Dial984.25
      -44.00 (-4.28%)
      Ramkrishna Forg693.40
      -27.06 (-3.76%)
      Rainbow Childrens1,443.70
      -46.10 (-3.10%)

      DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

      DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

      By using this site, you agree to the Terms of Service and Privacy Policy.

      The Economic Times